Mullane Michael P相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Impact of Updated NCCN Guidelines on Clinical Management and Risk Communication for CHEK2 p.I157T Carriers in Breast Cancer

更新后的NCCN指南对乳腺癌CHEK2 p.I157T携带者临床管理和风险沟通的影响

doi:10.21203/rs.3.rs-8833709/v1

Kell, Emma A; Mullane, Michael P; Geurts, Jennifer L; Ramczyk, Brenda; Bachinski, Tessa M

发表日期：2026

文献求助收藏

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

E1912 研究中，接受伊布替尼治疗的 CLL 患者中，IGHV 突变状态与耐受性和长期疾病控制之间的关系

期刊:Blood Advances

影响因子:7.1

doi:10.1182/bloodadvances.2024013474

Shanafelt, Tait D; Wang, Xin Victoria; Hanson, Curtis A; Paietta, Elisabeth; O'Brien, Susan; Barrientos, Jacqueline; Jelinek, Diane F; Braggio, Esteban; Leis, Jose F; Zhang, Cong Christine; Barr, Paul M; Cashen, Amanda F; Mato, Anthony R; Singh, Avina K; Mullane, Michael P; Little, Richard F; Erba, Harry; Stone, Richard M; Litzow, Mark; Tallman, Martin; Kay, Neil E

发表日期：2025

文献求助收藏

Characteristics of patients with hematologic malignancies without seroconversion post-COVID-19 third vaccine dosing

未发生血清转化的血液系统恶性肿瘤患者在接种第三剂新冠疫苗后的特征

期刊:Biology Methods and Protocols

影响因子:1.3

doi:10.1093/biomethods/bpad002

Hallmeyer, Sigrun; Thompson, Michael A; Fitzpatrick, Veronica; Liao, Yunqi; Mullane, Michael P; Medlin, Stephen C; Copeland, Kenneth; Weese, James L

发表日期：2023

文献求助收藏

Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

伊布替尼-利妥昔单抗联合化疗免疫疗法治疗慢性淋巴细胞白血病的长期疗效：E1912试验的最新结果

影响因子:23.1

doi:10.1182/blood.2021014960

Shanafelt, Tait D; Wang, Xin Victoria; Hanson, Curtis A; Paietta, Elisabeth M; O'Brien, Susan; Barrientos, Jacqueline; Jelinek, Diane F; Braggio, Esteban; Leis, Jose F; Zhang, Cong Christine; Coutre, Steven E; Barr, Paul M; Cashen, Amanda F; Mato, Anthony R; Singh, Avina K; Mullane, Michael P; Little, Richard F; Erba, Harry; Stone, Richard M; Litzow, Mark; Tallman, Martin; Kay, Neil E

细胞生物学

免疫/内分泌

发表日期：2022

文献求助收藏

Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies

真实世界中第三剂新冠疫苗在血液系统恶性肿瘤患者中的剂量和抗体反应

期刊:Journal of Patient-Centered Research and Reviews

影响因子:1.5

doi:10.17294/2330-0698.1952

Thompson, Michael A; Hallmeyer, Sigrun; Fitzpatrick, Veronica E; Liao, Yunqi; Mullane, Michael P; Medlin, Stephen C; Copeland, Kenneth; Weese, James L

发表日期：2022

文献求助收藏

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib.

可测量的残留病灶并不妨碍接受伊布替尼治疗的慢性淋巴细胞白血病患者获得较长的无进展生存期

影响因子:23.1

doi:10.1182/blood.2020010146

Wang Xin Victoria, Hanson Curtis A, Tschumper Renee C, Lesnick Connie E, Braggio Esteban, Paietta Elisabeth M, O'Brien Susan, Barrientos Jacqueline C, Leis Jose Francisco, Zhang Cong Christine, Coutre Steven E, Barr Paul M, Cashen Amanda F, Mato Anthony R, Singh Avina K, Mullane Michael P, Erba Harry, Stone Richard, Litzow Mark R, Tallman Martin S, Shanafelt Tait D, Kay Neil E

细胞生物学

发表日期：2021

文献求助收藏

Coordinating an Oncology Precision Medicine Clinic Within an Integrated Health System: Lessons Learned in Year One

在综合医疗体系内协调肿瘤精准医疗诊所：第一年的经验教训

期刊:Journal of Patient-Centered Research and Reviews

影响因子:1.5

doi:10.17294/2330-0698.1639

Thompson, Michael A; Godden, Jennifer J; Wham, Deborah; Ruggeri, Antony; Mullane, Michael P; Wilson, Amanda; Virani, Shamsuddin; Weissman, Scott M; Ramczyk, Brenda; Vanderwall, Pamela; Weese, James L

发表日期：2019

文献求助收藏